UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
June
27, 2006
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
750
Lexington Avenue, 20th Floor
New
York, NY 10022
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): o
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
XTL
Biopharmaceuticals to Present at the
Jefferies
Life Sciences Conference
New
York, NY, June
26, 2006
- XTL
Biopharmaceuticals, Ltd. (Nasdaq: XTLB, LSE: XTL;TASE:XTL)announced today that
Ron Bentsur, the Company’s Chief Executive Officer, is scheduled to present at
the Jefferies Life Sciences Conference. Mr. Bentsur’s presentation will take
place on Wednesday, June 28, 2006 at 10:45 am EDT at The Mandarin Oriental
Hotel
in New York City.
A
live
audio webcast of Mr. Bentsur's presentation will be available at http://www.wsw.com/webcast/jeff11/xtlb/.
An
archived version of the webcast will be available following the conclusion
of
the live presentation.
About
XTL Biopharmaceuticals, Ltd.
XTL
Biopharmaceuticals Ltd. ("XTLbio") is engaged in the acquisition, development
and commercialization of therapeutics for the treatment of infectious diseases,
with a focus on hepatitis C. XTLbio is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is
currently in a Phase 1 clinical trial in chronic hepatitis C patients. XTLbio
is
also developing XTL-6865 - a combination of two monoclonal antibodies against
the hepatitis C virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTLbio’s hepatitis C pipeline also includes several
families of pre-clinical hepatitis C small molecule inhibitors. In
addition, XTLbio has out-licensed to Cubist Pharmaceuticals an antibody
therapeutic against hepatitis B, HepeX-B, which has recently completed a Phase
2b clinical study in hepatitis B liver transplant patients. XTLbio is publicly
traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE:
XTL; TASE: XTL).
Contact:
Ron
Bentsur
Chief
Executive Officer
(212)
531-5971
rbentsur@xtlbio.com
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
|
|
| |
XTL
BIOPHARMACEUTICALS LTD. |
|
|
|
| Date: June
27, 2006 |
By: |
/s/ Jonathan
Burgin |
| |
Jonathan
Burgin |
| |
Chief
Financial Officer
|